VEGFA and cancer: VEGF-A, often referred to as VEGF without a suffix [4], is the sole target of bevacizumab, a humanized monoclonal antibody approved for the treatment of colorectal and other cancers [55] and aflibercept (VEGF Trap, known in the US as ziv-aflibercept), is a recombinant fusion protein with receptor components of VEGFR-1 and VEGFR-2 that binds multiple ligands in the angiogenesis network (VEGF-A, VEGF-B, and PlGF) [56].